Skip to Main Content

Author Details

Pavlo Gilchuk
Vanderbilt University Medical Center
2005
71
32
PMIDPaper TitleJournal TitlePublished Year
37029928Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.Cell Rep2023
38039973A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.Cell Rep Med2023
37131834Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system.Res Sq2023
34901783Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.iScience2022
35584193Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.PLoS Pathog2022
35578733Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape.STAR Protoc2022
35780813Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.Chest2022
35132398A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.Med2022
35082794Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.Front Immunol2022
33259788Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.Cell Host Microbe2021
33852862Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.Cell Rep2021
33907753A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.bioRxiv2021
33594356SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.Res Sq2021
33532768Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.bioRxiv2021
33664494Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.Nat Med2021
33691139Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.Cell2021
33501445Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.bioRxiv2021
34411541Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.Cell Rep2021
34548634Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.Nat Microbiol2021
34481543A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.Immunity2021
34715022Pan-ebolavirus protective therapy by two multifunctional human antibodies.Cell2021
34153975In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.Nature2021
34214467Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell.Cell Rep2021
34335620Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.Front Immunol2021
33972937Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.bioRxiv2021
32511409Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.bioRxiv2020
32023489Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.Immunity2020
33229516Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions.Proc Natl Acad Sci U S A2020
33398272Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.bioRxiv2020
32747832Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics.Nat Biomed Eng2020
32935107Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.bioRxiv2020
32668443Potently neutralizing and protective human antibodies against SARS-CoV-2.Nature2020
32320678Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.Cell Host Microbe2020
32511414Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.bioRxiv2020
30518655Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.J Virol2019
31757769Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.Cell Host Microbe2019
31553872Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8<sup>+</sup> Lung-Resident Memory T Cells.ACS Nano2019
31100268A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.Cell2019
30760926High frequency of shared clonotypes in human B cell receptor repertoires.Nature2019
30996276Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.Nat Commun2019
29736037Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.Nat Microbiol2018
30107445Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.J Infect Dis2018
30107272Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.Biomaterials2018
30029854Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.Immunity2018
29991715A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.Nat Commun2018
29982718Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.J Infect Dis2018
30138408Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.PLoS Pathog2018
30110637Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.Cell Rep2018
30485806Identifying and Tracking Low-Frequency Virus-Specific TCR Clonotypes Using High-Throughput Sequencing.Cell Rep2018
27718206Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols.Methods Mol Biol2017
  • 1 - 50 of 71

Recommended Authors

Sebastian Weigang
Institute of Virology, Freiburg University Medical Center, University of Freiburg
Career Start Year 2018
Number of shared co-authors 4
Tianyang Mao
Yale University School of Medicine
Career Start Year 2017
Number of shared co-authors 0
Nisar Farhat
University of California los angeles
Career Start Year 2016
Number of shared co-authors 2
Paul V Thomas
Walter Reed Army Institute of Research
Career Start Year 2015
Number of shared co-authors 6
Yi Shi
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 2014
Number of shared co-authors 1
Carolina Lucas
Yale School of Medicine
Career Start Year 2014
Number of shared co-authors 0
Nicholas Dambrauskas
Center for Global Infectious Disease Research, Seattle Children's Research Institute
Career Start Year 2013
Number of shared co-authors 1
Wilfredo F Garcia-Beltran
Ragon Institute of MGH
Career Start Year 2012
Number of shared co-authors 3
Hongjie Xia
University of Texas Medical Branch
Career Start Year 2012
Number of shared co-authors 2
Yiska Weisblum
Rockefeller University
Career Start Year 2011
Number of shared co-authors 0
Goran Bajic
Icahn School of Medicine at Mount Sinai
Career Start Year 2010
Number of shared co-authors 6
Thomas J Gardner
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 2
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 3
Melissa M Coughlin
Centers for Disease Control and Prevention
Career Start Year 2006
Number of shared co-authors 7
John T Bates
University of Mississippi Medical Center
Career Start Year 2005
Number of shared co-authors 2
David Noah Sather
Center for Global Infectious Disease Research, Seattle Children's Hospital
Career Start Year 2005
Number of shared co-authors 3
Lingshu Wang
National Institute of Allergy and Infectious Disease, National Institute of Health
Career Start Year 2003
Number of shared co-authors 8
Fabian Schmidt
The Rockefeller University
Career Start Year 2002
Number of shared co-authors 2
Kayvon Modjarrad
Center for Infectious Diseases Research, Walter Reed Army Institute of Research
Career Start Year 2002
Number of shared co-authors 4
William D Martin
EpiVax Inc.
Career Start Year 2001
Number of shared co-authors 2
Mansun Law
The Scripps Research Institute
Career Start Year 1998
Number of shared co-authors 3
Gary P Kobinger
University of Texas Medical Branch
Career Start Year 1997
Number of shared co-authors 6
Vladimir Vigdorovich
Center for Global Infectious Disease Research, Seattle Children's Hospital
Career Start Year 1997
Number of shared co-authors 1
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 7
Theodora Hatziioannou
The Rockefeller University
Career Start Year 1995
Number of shared co-authors 2
Leonard Moise
EpiVax Inc.
Career Start Year 1991
Number of shared co-authors 2
Anne S De Groot
University of Georgia
Career Start Year 1989
Number of shared co-authors 2
Bart L Haagmans
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 5
Timothy R Fouts
Profectus BioSciences Inc.
Career Start Year 1981
Number of shared co-authors 0
Christopher B Wilson
Drukier Institute for Children's Health
Career Start Year 1976
Number of shared co-authors 6

Collaborators

James E Crowe
Vanderbilt University Medical Center
Co-authored papers 50
Robert H Carnahan
Vanderbilt University Medical Center
Co-authored papers 22
Michael S Diamond
Washington University School of Medicine
Co-authored papers 17
Rita E Chen
Co-authored papers 16
Natalia A Kuzmina
University of Texas Medical Branch, USA Galveston National Laboratory
Co-authored papers 10
Laura A VanBlargan
Washington University School of Medicine
Co-authored papers 10
Galit Alter
Co-authored papers 8
Adrianus C M Boon
Co-authored papers 7
Pei-Yong Shi
University of Texas Medical Branch
Co-authored papers 7
Bronwyn M Gunn
Co-authored papers 7
Larissa B Thackray
Washington University School of Medicine
Co-authored papers 5
Xuping Xie
University of Texas Medical Branch
Co-authored papers 5
Kathryn M Edwards
Vanderbilt University Medical Center
Co-authored papers 3
Jens Meiler
Vanderbilt University
Co-authored papers 3
Scott A Handley
Washington University School of Medicine
Co-authored papers 3
Ralph S Baric
University of North Carolina
Co-authored papers 3
James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Co-authored papers 3
Dan H Barouch
Co-authored papers 3
Jill M Pulley
Vanderbilt University School of Medicine
Co-authored papers 2
William H Hildebrand
University of Oklahoma Health Sciences Center
Co-authored papers 2
Gordon R Bernard
Vanderbilt University
Co-authored papers 2
Laura J Stevens
Vanderbilt University Medical Center
Co-authored papers 2
Mark R Denison
Vanderbilt University Medical Center
Co-authored papers 2
Isaac P Thomsen
Vanderbilt University Medical Center
Co-authored papers 2
Stuart Weston
University of Maryland School of Medicine
Co-authored papers 2
Jean-Jacques Muyembe-Tamfum
National Institute of Biomedical Research (INRB)
Co-authored papers 2
Ted M Ross
Center for Vaccines and Immunology, University of Georgia
Co-authored papers 2
Ian A Wilson
The Scripps Research Institute, USA The Skaggs Institute for Chemical Biology
Co-authored papers 2
Todd W Rice
Vanderbilt University Medical Center
Co-authored papers 2
Allison P Wheeler
Vanderbilt University Medical Center
Co-authored papers 2
Release 1.2